Mirabegron, alone and in combination, in the treatment of overactive bladder: real-world evidence and experience

Sara J. Allison and William Gibson

Abstract: Overactive bladder (OAB), the syndrome characterized by urgency, with or without urgency incontinence, usually with frequency and nocturia, in the absence of infection or other pathology, is a common, distressing and often debilitating condition with a high prevalence in the general population. For many years, the only available pharmacological treatment for OAB were the antimuscarinic agents. More recently, mirabegron, a selective agonist of the β3 adrenergic receptor, has become available. In this article we review the current evidence and experience of its use.

Keywords: overactive bladder, urinary incontinence, mirabegron, beta-3 agonist, pharmacotherapy, lower urinary tract symptoms

Received: 26 July 2018; revised manuscript accepted: 28 August 2018.

Background

Lower urinary tract symptoms (LUTS), including urgency, frequency and nocturia, are common in the general population and increase in prevalence with ageing. Overactive bladder (OAB), the clinically defined symptom complex of urgency, with or without urgency incontinence, usually with frequency and nocturia, in the absence of infection or other pathology, is the most common cause of incontinence in both men and women, and the prevalence of OAB increases with age. OAB and other forms of urinary incontinence (UI) are stigmatizing conditions with significant impacts on quality of life and are commonly under-reported by patients for multiple reasons, including belief that incontinence is normal post-partum or as part of ageing, or that treatment is not available. OAB is a disorder of the filling phase of the bladder, characterized by the presence of urgency, the sudden, compelling desire to void which is difficult to defer. The exact underlying cause of urgency and of OAB remains the subject of much debate in the literature, with there being evidence for the urothe- lium, detrusor, and brain being involved in the pathophysiology of OAB. In those without lower urinary tract dysfunction, voiding is under voluntary control and continence is maintained by a complex interaction between the bladder and numerous areas of the brain, including the frontal and prefrontal cortices, the periaqueductal grey matter and the pontine micturition centre. Neurological diseases, including the accumulation of white matter hyperintensities on MRI, cerebrovascular disease and dementia are all strongly associated with the development of LUTS in later life. As such, OAB cannot be considered simply as a disease of the bladder and lower urinary tract. Although conservative management options consider a whole-person approach, encompassing fluid intake, urgency suppression and bladder retraining, pharmacological agents are all directed at the bladder itself.

Treatment of OAB

The earliest account of treatment for incontinence was written by Pliny the Elder in AD77, who advocated giving children boiled mice in their food as a treatment for bedwetting. Beyond this, for many years the only available pharmacological options for treating OAB were anticholinergic drugs. Oxybutynin, a non-selective antagonist of the muscarinic receptor, became available in the 1970s and has been shown in multiple randomized controlled trials (RCTs) to be effective in reducing
symptom burden in OAB,\textsuperscript{18–21} and experience of its use means that clinicians are well-versed in its efficacy, tolerability and side-effect profile. It has been long recognized that oxybutynin carries a significant burden of adverse drug reactions, with anticholinergic side-effects being common, including constipation, dry mouth and blurred vision.\textsuperscript{18,22} Dry mouth occurs in up to 80\% of those taking oxybutynin,\textsuperscript{23} and discontinuation rates are high, with a systematic review of OAB drugs in 2011 finding discontinuation rates up to 31\% at 12 weeks in RCTs, up to 80\% in analyses of claims data, and with half of patients not refilling their prescriptions after the first script issued.\textsuperscript{24} Despite this, oxybutynin is recommended as first-line pharmacotherapy in several national guidelines, including those of the National Institute of Health and Clinical Excellence in the UK.\textsuperscript{25} This is most likely on cost grounds, as oxybutynin has the lowest acquisition cost of the available medications for OAB.\textsuperscript{26} Newer and more selective anticholinergics for the treatment of OAB have been developed, including tolterodine in the 1990s,\textsuperscript{27} with solifenacin,\textsuperscript{28} darifenacin\textsuperscript{29} and fesoterodine\textsuperscript{30} becoming available for clinical use in the 2000s. The newer anticholinergics are more selective for the M2 and M3 receptor subtypes\textsuperscript{31} and were developed in the hope that this increased selectivity would improve efficacy and reduce side-effects. A Cochrane review of the available anticholinergics for OAB suggested that tolterodine conferred a lower risk of xerostomia than oxybutynin, that solifenacin demonstrated superior efficacy to tolterodine, and that fesoterodine likewise was more efficacious than tolterodine.\textsuperscript{32}

**Anticholinergic concerns**

Exposure to drugs with anticholinergic effects has been lined to cognitive decline in older adults\textsuperscript{33} with cumulative exposure to anticholinergic drugs being linked to an increased risk of dementia.\textsuperscript{34} Normal ageing is associated with changes to the blood–brain barrier, with increased permeability to inflammatory mediators and drugs,\textsuperscript{35} and lipophilic drugs such as oxybutynin are inherently able to cross the blood–brain barrier relatively freely.\textsuperscript{36} This may be why oxybutynin in particular, of the bladder antimuscarinics, has been shown, in high doses, to be associated with impaired cognitive performance.\textsuperscript{37,38} There is evidence that the newer and more M2/M3-specific antimuscarinics have little or no impact on cognition, with cognitive safety data available for trospium,\textsuperscript{39} darifenacin,\textsuperscript{40} solifenacin\textsuperscript{41} and fesoterodine\textsuperscript{42} in cognitively intact older people. It has therefore been suggested that the use of oxybutynin should be avoided in the elderly, and in particular the frail elderly.\textsuperscript{43} Anticholinergic side-effects, and in particular dry mouth, are the most commonly cited reasons for discontinuing treatment for OAB with antimuscarinic drugs.\textsuperscript{24} Older adults are also more likely to be subjected to polypharmacy, the prescription of five or more medications,\textsuperscript{44} which exponentially increases the risk of drug–drug interaction and potential for harm.\textsuperscript{45} There is evidence from case-control studies that exposure to drugs with an Anticholinergic Cognitive Burden Scale (ACB) of 3 confers higher odds of developing dementia, with an odds ratio of 1.11 [95\% confidence interval (CI) 1.08–1.14] when compared to no anticholinergic exposure.\textsuperscript{46} However, ‘gastrointestinal’ and ‘antipsychotic’ drugs with an ACB score of 3 did not demonstrate this association, and no dose–response effect was demonstrated. Furthermore, the ‘urological’ drugs were considered as a class, without the differential cognitive risks, lipophilicity, CNS penetration and receptor subtype affinity being considered. In addition, objective serum anticholinergic activity has been found to have no link to cognitive impairment in randomized studies.\textsuperscript{47} At present, therefore, there is no evidence to suggest the complete avoidance of the newer antimuscarinics in older people is necessary.

Across patient groups, the typical anticholinergic side-effects of dry mouth and constipation are particularly bothersome, which is reflected in the poor adherence rates with anticholinergics. Therefore, national and international guidelines for the treatment of OAB emphasize conservative methods such as bladder retraining, fluid intake normalization and urgency suppression techniques prior to the use of pharmacotherapy,\textsuperscript{48} and much research has focused on finding alternative, non-anticholinergic drugs for the treatment of OAB.

**Development of mirabegron**

Initial interest in β3 receptors centred around their role in thermogenesis in adipose tissue and potential for development as a treatment for obesity,\textsuperscript{49} which proved a therapeutic dead end. However, investigation of the role of β3 in detrusor relaxation suggested that β3 agonists could be a useful therapeutic option for OAB,\textsuperscript{50} and mirabegron was developed by Astellas Pharma Inc., Japan.\textsuperscript{51} Mirabegron is currently the only available β3 agonist. It was approved for clinical use in
the USA in 2012, and is a potent and selective agonist of the β3 adrenoreceptor. Mirabegron has been studied as both monotherapy and as combination therapy as a treatment for OAB. At present, mirabegron is the only available β3 agonist, although a second agent, vibegron, is undergoing phase III trials.

Mirabegron as monotherapy

Following development and testing in phase I and II trials, mirabegron as monotherapy for OAB was studied in numerous phase II and III RCTs, with both placebo and active controls.

The SCORPIO trial compared mirabegron to placebo and tolterodine in people with OAB in Europe and Asia. Khullar and colleagues randomized a total of 1978 adults with OAB in a 1:1:1:1 ratio comparing placebo, mirabegron 50 mg, mirabegron 100 mg, and tolterodine ER 4 mg. Tolterodine was included as an active control but formal statistical comparisons with tolterodine were not performed. The mirabegron groups had statistically significant reduction in the number of incontinence episodes per 24 h from baseline (−1.57 and −1.46 for 50 mg and 100 mg respectively) compared to placebo and in number of micturitions per 24 h, with 1.93 and −1.99 fewer for mirabegron 50 mg and 100 mg respectively compared to 1.34 fewer in the placebo arm. Similarly, in the ARIES trial, Nitti and colleagues randomized 1329 adults in North America to receive placebo, mirabegron 50 mg, or mirabegron 100 mg in a 1:1:1 ratio. Over the 12 week follow-up period there was a significantly greater improvement in the key end-point, incontinence episodes per 24 h, in the mirabegron groups (−1.47 and −1.63 for 50 mg and 100 mg respectively) compared to the placebo group (−1.13). As often seen in OAB trials, there was a significant placebo effect. Secondary endpoints, including severity of urgency, nocturia and OAB-q bother scores also improved, with more in the mirabegron groups than the placebo arm. The third phase III trial, Capricorn, compared mirabegron 25 mg and 50 mg to placebo in 1305 adults with OAB in Europe and North America, across 151 sites. They reported significantly greater improvements for mirabegron 25 mg and 50 mg daily compared to placebo for mean number of incontinence episodes per day (−1.36 and −1.38 respectively), as well as improvements in number of micturitions and improvements in quality of life measures.

Looking specifically at older adults, Wagg and colleagues performed a prospective subgroup analysis of these three trials analysing those aged ≥65 and ≥75 years of age. There were no statistically significant differences across the age groups. The frequency of treatment emergent adverse events (TEAEs) was also similar across the age groups, with no increase in TEAEs in older adults with mirabegron. Unsurprisingly, the incidence of dry mouth was significantly higher in the tolterodine groups, with a sixfold higher occurrence rate than in the mirabegron groups.

All three of the initial phase III studies were of relatively short duration, each being 12 weeks in length. Longer-term studies, with follow-up periods of up to a year, have also been reported. Chappel and colleagues reported a 12-month trial of mirabegron, 50 mg and 100 mg, versus tolterodine extended release 4 mg, randomizing 2444 adults with OAB. They collected efficacy and safety data at 1, 3, 6, 9 and 12 months, and demonstrated similar efficacy across the three groups, including a reduction in number of incontinence episodes per 24 h (−1.01, −1.24, and −1.26 for mirabegron 25 mg, 50 mg, and tolterodine respectively), and micturitions per 24 h (−1.27, −1.41, and −1.39, respectively). Serious TEAE rates were likewise similar for the three groups, at 5.2% for mirabegron 50 mg, 6.2% for mirabegron 100 mg, and 5.4% for tolterodine. TEAEs of all levels of severity were reported in 59.7%, 61.3% and 62.6%, respectively, and were most commonly hypertension, gastrointestinal disturbance (predominantly constipation), and headache, which occurred equally across the three groups. They conclude that mirabegron demonstrated an acceptable safety and tolerability profile with improvements in OAB symptoms at the first measurable time point of month 1, with sustained improvement throughout 12 months, and that the effect size was similar to those of antimuscarinic therapy.

Ciu and colleagues performed a systematic review of trials of mirabegron in 2014, including four RCTs with a total of 5791 participants. They reported the standardized mean difference (SMD) from baseline to study completion, comparing mirabegron to the placebo arm, and found that mirabegron was effective in treating OAB, with a greater reduction in incontinence episodes of 0.44 episodes/day for mirabegron versus placebo, as well as reduced micturitions per day and episodes of urgency. They also analysed TEAEs,
finding similar rates of discontinuation for TEAEs in the active and placebo groups, with pooled odds ratio of 1.22 (95% CI 0.84–1.76), and the authors therefore concluded that mirabegron is an efficacious and well-tolerated treatment option for OAB.

It is a feature of OAB trials that the primary endpoints, such as micturitions per 24 h, incontinence episodes and voided volumes often show modest improvements, and it has been suggested that health-related quality of life (HRQoL) outcomes are a more valid measure of success.61 In view of this, Castro-Diaz and colleagues performed a post-hoc responder analysis of pooled data from three randomized, 12-week placebo controlled trials.54,55,57 They defined a responder as a ≥50% decrease from baseline to final visit in mean number of incontinence episodes per 24 h incontinence episodes for incontinence, and a patient with ≤8 micturitions per 24 h at final assessment for urinary frequency. Within these groups, there was a statistically significantly greater improvement for patient-reported outcomes over placebo for patient perception of their bladder condition, and statistically significant improvements from baseline to final visit relative to placebo in OAB-q total HRQoL and the OAB-q subscales of coping, concern and sleeping, but not social interaction, suggesting that as well as having measurable impact on objective indices, mirabegron as monotherapy has a positive impact on quality of life.

Wagg and colleagues reported a longer-term and real-world study of mirabegron, using persistence with therapy as a marker of efficacy and tolerability.63 They reported a 12 month retrospective cohort study of 6189 patients in the United Kingdom prescribed either an antimuscarinic or mirabegron. Their data suggested that antimuscarinics as a group were taken for less time than mirabegron, with the median days on therapy for antimuscarinics ranging from 27 days for oxybutynin IR and tolterodine IR to 55 for fesoterodine and 56 for solifenacin, compared to 101 days for mirabegron. Similarly, the mean duration of treatment was 86 days for oxybutynin IR, 130 days for solifenacin and 160 days for mirabegron. As a retrospective review of prescription data, these data were influenced by the practice of issuing prescriptions 1 month at a time, and there was a significant discontinuation rate for all agents at 30 days. Commonly reported side-effects of mirabegron were hypertension (9.1%), nasopharyngitis (4.1%) and urinary tract infection (3.1%). The authors conclude that mirabegron was associated with significantly longer time to discontinuation, greater persistence at 1 year, and better adherence with therapy than the antimuscarinic agents.

Mirabegron has not been compared to intravesical onobotulinumtoxin A in a head-to-head trial. However, Freemantle and colleagues conducted a network meta-analysis of 19 available trials to construct a network meta-regression comparing the two agents.64 They concluded that onobotulinumtoxin A and mirabegron were both more efficacious than placebo in the treatment of idiopathic OAB, and that onabotulinumtoxin A may be superior to mirabegron in improving symptoms of UI, urgency and frequency.

The use of mirabegron in combination with other agents

There has also been interest in using mirabegron in combination with antimuscarinic drugs for treatment-resistant OAB. Given that the two groups have different modes of action, it is reasonable to think that combination therapy would have advantages over monotherapy.

The Symphony trial, a multinational phase II double-blind RCT, compared 1306 people with OAB across 12 groups, 6 combination groups (solifenacin 2.5, 5 or 10 mg plus mirabegron 25 or 50 mg), 5 monotherapy groups (solifenacin 2.5, 5 or 10 mg, or mirabegron 25 or 50 mg), or placebo, with a 2 week placebo run-in period. Compared to solifenacin 5 mg monotherapy, at 12 weeks follow up those treated with mirabe- gron 25 mg or 50 mg in combination with solifenacin 2.5 mg, 5 mg and 10 mg had significantly reduced numbers of micturitions per 24 h, with a trend for increasing effect with increasing doses of solifenacin and mirabegron. All treatment groups, including placebo, demonstrated a reduction in the number of urgency episodes from baseline, and none of the active treatment groups significantly reduced incontinence episodes compared with placebo.

Following this, the SYNERGY study was a larger phase III trial comparing solifenacin 5 mg in combination with mirabegron 25 mg and 50 mg with solifenacin 5 mg, mirabegron 25 mg and mirabegron 50 mg as monotherapy and placebo.65 Conducted at 425 sites in 42 countries, a total of 3398 participants were randomized in a
2:2:1:1:1:1 ratio to the combination groups and monotherapy/placebo groups respectively. Participants completed 2 weeks of placebo run-in prior to 12 weeks of therapy. As with Symphony, all the treatment groups demonstrated a reduction in UI episodes per 24 h, with a greater reduction in the combination therapy groups than monotherapy or placebo, with reductions of −1.34 for placebo, −1.7 and −1.76 for mirabegron 25 mg and 50 mg respectively, −1.79 for solifenacin 5 mg, −2.04 for mirabegron 25 mg with solifenacin 5 mg, and −1.98 for mirabegron 50 mg with solifenacin 5 mg. However, although the combined solifenacin 5 mg/mirabegron 50 mg arm was superior to solifenacin 5 mg monotherapy for UI episodes (mean adjusted difference of −0.2 episodes/24 h, 95% CI −0.44−0.04, p = 0.033), superiority to mirabegron 50 mg was not demonstrated (mean adjusted difference −0.23 95% CI −0.47, 0.01, p = 0.052). Pre-specified subgroup analysis demonstrated a small but statistically significant improvement for reduction in micturition episodes per 24 h and incontinence episodes per 24 h for both combination groups (mirabegron 25 mg and 50 mg with solifenacin 5 mg) compared to mirabegron and solifenacin monotherapy, with all active treatment groups having greater improvements in UI episodes/24 h versus placebo, with effect sizes for the combined therapy groups (combined solifenacin and mirabegron 25 mg group: −0.70 episodes/24 h and solifenacin/mirabegron 50 mg group −0.65 episodes/24 h) that were higher than those obtained with monotherapy (range −0.37 episodes/24 h for mirabegron 25 mg to −0.45 episodes/24 h for solifenacin 5 mg). It is interesting to note that there was no additional benefit from the higher dose of mirabegron when comparing the two combination arms, and taken as a whole the data from this trial did not show a consistent and clinically significant benefit from combining mirabegron with solifenacin.

The BESIDE study specifically recruited adults with OAB who had not responded to 4 weeks of therapy with solifenacin.67 Following single-blind 5 mg solifenacin run-in, those participants who reported at least one episode of incontinence on a three-day diary were randomized to receive either solifenacin 5 mg, solifenacin 10 mg or solifenacin 5 mg with mirabegron 25 mg, increasing to 50 mg after 4 weeks. A total of 2174 people entered the second phase of the study, and were randomized in a 1:1:1 ratio and followed for 12 weeks. The primary outcome measure was reduction in incontinence episodes from baseline, and secondary end-points included number of urgency episodes, mean voided volume, and nocturia, and patient perception of bladder condition score. There was a greater reduction in incontinence episodes per 24 h for the combination group than the solifenacin 5 mg group (−1.80 versus −1.53 respectively), and the combination was non-inferior to solifenacin 10 mg for the majority of the reported end-points. The incidence of TEAEs was lowest in the solifenacin 5 mg group (33.1%) and highest with solifenacin 10 mg (39.4%), with the combination group falling between these two at 35.9%. Classical anticholinergic effects, constipation and dry mouth, were the commonest TEAEs reported, and these were unsurprisingly highest in the solifenacin 10 mg group and similar in the combination and solifenacin 5 mg groups. This suggests that, although the effect of adding mirabegron and increasing the solifenacin dose were similar, the bothersome anticholinergic side-effects of higher-dose solifenacin could be avoided by adding mirabegron.

Given the well-reported issues concerning anticholinergic use in older adults,34 a pre-specified subgroup analysis of the BESIDE study was reported, analysing the results in the over-65 and over-75 age groups.68 Of the initial BESIDE group, 30.9% were aged 65 or over, and 8.9% were 75 or over. In the efficacy analysis there were no significant interactions between age group and treatment group for the ≥65 group (p = 0.825) or ≥75 group (p = 0.96), suggesting that age did not influence the efficacy of any of the three treatment arms. The older groups were more likely to have TEAEs, and in particular constipation was reported slightly more commonly in the ≥75 group in all three treatment arms, and the incidence of cardiovascular effects was <2% across the board. Cognitive adverse events were not specifically reported in this study. Additionally, a responder analysis to the BESIDE trial has also been reported,69 exploring if the reported changes to objective symptoms were translated to significant improvements in patient-reported outcomes (PRO). The authors defined PRO responders as those who achieved a change from baseline to end of treatment that exceeded the predefined minimally important difference on the OAB Questionnaire70 or the Patient Perception of Bladder Condition questionnaire.71 There were differences in favour of the combination arm compared to both solifenacin groups in the proportion of responders who reported a 50% reduction in
incontinence episodes and normalization of micturition frequency, and those receiving combination treatment had greater odds of achieving complete cure of incontinence [OR 1.47 (95% CI 1.17–1.84)] compared to solifenacin 5 mg monotherapy. It is worth noting that all the trials using mirabegron as a combination therapy have used solifenacin, as both agents share a common manufacturer. There are no trials using mirabegron in combination with other antimuscarinics or with onabotulinumtoxinA.

Conclusion
Taken as a whole, the available data suggest that mirabegron is broadly as effective as monotherapy for OAB across the age range when compared to antimuscarinic agents. Rates of TEAEs with mirabegron are similar to antimuscarinics, although the rates of anticholinergic side-effects, which are often cited by patients as being most bothersome, are significantly lower, which may explain the improved adherence and treatment longevity with mirabegron. Clinical experience and the responder analyses suggest that, for unknown reasons, some patients do not respond to antimuscarinics for OAB, and for these patients the availability of a new class of drug provides a valuable alternative therapeutic option. The results when using mirabegron in combination with solifenacin have been disappointing, with much less of an additional benefit than may have been hoped for based on the experience of monotherapy. However, responder analyses do suggest again that for some, selected, patients, the addition of mirabegron to an antimuscarinic will achieve a meaningful improvement in their symptoms, and that higher doses of antimuscarinics can be avoided by adding mirabegron to existing treatment. As such, mirabegron is proving to be a useful addition to the available treatment options for people with OAB, and in particular in people in whom anticholinergics may be undesirable, such as the elderly and those with preexisting neurological disease.

Funding
This research received no specific grant from any funding agency in the public, commercial or not-for-profit sectors.

Conflict of interest statement
WG has received speaker fees and research funding from Astellas and Pfizer. SJA has no conflicts to declare.

References
1. Irwin DE, Milsom I, Hunskaar S, et al. Population-based survey of urinary incontinence, overactive bladder, and other lower urinary tract symptoms in five countries: results of the EPIC study. *Eur Urol* 2006; 50: 1306–1314; discussion 1314–1315.
2. Hannestad YS, Rortveit G, Sandvik H, et al. A community-based epidemiological survey of female urinary incontinence: the Norwegian EPINCONT study. Epidemiology of Incontinence in the County of Nord-Trøndelag. *J Clin Epidemiol* 2000; 53: 1150–1157.
3. Abrams P, Artibani W, Cardozo L, et al. Reviewing the ICS 2002 terminology report: the ongoing debate. *Neurol Urodyn* 2009; 28: 287.
4. Barentsen JA, Visser E, Hofstetter H, et al. Severity, not type, is the main predictor of decreased quality of life in elderly women with urinary incontinence: a population-based study as part of a randomized controlled trial in primary care. *Health Qual Life Outcomes* 2012; 10: 153.
5. Brazell HD, O’Sullivan DM and Lasala CA. Does the impact of urinary incontinence on quality of life differ based on age? *Int Urogynecol J* 2013; 24: 2077–2080.
6. Irwin DE, Milsom I, Kopp Z, et al.; EPIC Study Group. Symptom bother and health care-seeking behavior among individuals with overactive bladder. *Eur Urol* 2008; 53: 1029–1037.
7. Shaw C, Tansey R, Jackson C, et al. Barriers to help seeking in people with urinary symptoms. *Fam Pract* 2001; 18: 48–52.
8. de Groat WC. The urothelium in overactive bladder: passive bystander or active participant? *Urology* 2004; 64(6 Suppl.): 7–11.
9. Bradin AF. A myogenic basis for the overactive bladder. *Urology* 1997; 50(6A Suppl.): 57–67; discussion 68–73.
10. Sakakibara R, Panicker J, Fowler CJ, et al. Is overactive bladder a brain disease? The pathophysiological role of cerebral white matter in the elderly. *Int J Urol* 2014; 21: 33–38.
11. Fowler CJ, Griffiths D and de Groat WC. The neural control of micturition. *Nat Rev Neurosci* 2008; 9: 453–466.
12. Burney TL, Senapati M, Desai S, et al. Acute cerebrovascular accident and lower urinary tract dysfunction: a prospective correlation of the site of brain injury with urodynamic findings. *J Urol* 1996; 156: 1748–1750.
13. Kuchel GA, et al. Localization of brain white matter hyperintensities and urinary incontinence...
in community-dwelling older adults. *J Gerontol A Biol Sci Med Sci* 2009; 64(8): 902–909.

14. Tadic S, Griffiths D, Murrin A, et al. Structural damage of brain’s white matter affects brain–bladder control in older women with urgency incontinence. In: *Joint Annual Meeting of the International Continence Society, ICS and International Urogynecological Association, IUGA*, 2010, Toronto, ON, Canada.

15. Salmon MA. An historical account of nocturnal enuresis and its treatment. *Proc R Soc Med* 1975; 68: 443–445.

16. Noronha-Blob L and Kachur JF. Enantiomers of oxybutynin: in vitro pharmacological characterization at M1, M2 and M3 muscarinic receptors and in vivo effects on urinary bladder contraction, mydriasis and salivary secretion in guinea pigs. *J Pharmacol Exp Ther* 1991; 256: 562–567.

17. Thompson IM and Lauvetz R. Oxybutynin in bladder spasm, neurogenic bladder, and enuresis. *Urology* 1976; 8: 452–454.

18. Riva D and Casolati E. Oxybutynin chloride in the treatment of female idiopathic bladder instability: results from double blind treatment. *Clin Exp Obstet Gynecol* 1984; 11: 37–42.

19. Zorzitto ML, Holliday PJ, Jewett MA, et al. Oxybutynin chloride for geriatric urinary dysfunction: a double-blind placebo-controlled study. *Age Ageing* 1989; 18: 195–200.

20. Primus G and Pummer K. Oxybutynin hydrochloride in the management of detrusor instability. *Int Urol Nephrol* 1990; 22: 243–248.

21. Malone-Lee J, Lubel D and Szyoni G. Low dose oxybutynin for the unstable bladder. *BMJ* 1992; 304: 1053.

22. Thuroff JW, Bunke B, Ebner A, et al. Randomized, double-blind, multicenter trial on treatment of frequency, urgency and incontinence related to detrusor hyperactivity: oxybutynin versus propantheline versus placebo. *J Urol* 1991; 145: 815–816; discussion 816–817.

23. Baigrie RJ, Kelleher JP, Fawcett DP, et al. Oxybutynin: is it safe? *Br J Urol* 1988; 62: 319–322.

24. Sexton CC, Notte SM, Maroulis C, et al. Persistence and adherence in the treatment of overactive bladder syndrome with anticholinergic therapy: a systematic review of the literature. *Int J Clin Pract* 2011; 65: 567–585.

25. NICE UK. *CG171 urinary incontinence in women*. http://guidance.nice.org.uk/CG171/NICEGuidance/pdf/English (2013, accessed September 1 2018).

26. Ko Y, Malone DC and Armstrong EP. Pharmacoeconomic evaluation of antimuscarinic agents for the treatment of overactive bladder. *Pharmacotherapy* 2006; 26: 1694–1702.

27. Stahl MM, Ekström B, Sparf B, et al. Urodynamic and other effects of tolterodine: a novel antimuscarinic drug for the treatment of detrusor overactivity. *Neurourol Urodyn* 1995; 14: 647–655.

28. Chapple CR, Rechberger T, Al-Shukri S, et al. Randomized, double-blind placebo- and tolterodine-controlled trial of the once-daily antimuscarinic agent solifenacin in patients with symptomatic overactive bladder. *BJU Int* 2004; 93: 303–310.

29. Chapple C, Steers W, Norton P, et al. A pooled analysis of three phase III studies to investigate the efficacy, tolerability and safety of darifenacin, a muscarinic M3 selective receptor antagonist, in the treatment of overactive bladder. *BJU Int* 2005; 95: 993–1001.

30. Chapple C, Van Kerrebroeck P, Tubaro A, et al. Clinical efficacy, safety, and tolerability of once-daily fesoterodine in subjects with overactive bladder. *Eur Urol* 2007; 52: 1204–1212.

31. Chess-Williams R. Potential therapeutic targets for the treatment of detrusor overactivity. *Expert Opin Ther Targets* 2004; 8: 95–106.

32. Madhuvrata P, Cody JD, Ellis G, et al. Which anticholinergic drug for overactive bladder symptoms in adults. *Cochrane Database Syst Rev* 2012; 1: CD005429.

33. Mulsant BH, Pollock BG, Kirshner M, et al. Serum anticholinergic activity in a community-based sample of older adults: relationship with cognitive performance. *Arch Gen Psychiatry* 2003; 60: 198–203.

34. Gray SL, Anderson ML, Dublin S, et al. Cumulative use of strong anticholinergics and incident dementia: a prospective cohort study. *JAMA Intern Med* 2015; 175: 401–407.

35. Zlokovic BV. The blood–brain barrier in health and chronic neurodegenerative disorders. *Neuron* 2008; 57: 178–201.

36. Scheife R and Takeda M. Central nervous system safety of anticholinergics drugs for the treatment of overactive bladder in the elderly. *Clin Ther* 2005; 27: 144–153.

37. Kay G, Kardiasmenos K and Crook T. Abstracts of the International Continence Society 36th Annual Meeting, Christchurch, New Zealand, 27 November–1 December 2006. *Neurourol Urodyn* 2006; 25: 507–671.
38. Yamamoto S, Maruyama S, Ito Y, et al. Effect of oxybutynin and imidafenac on central muscarinic receptor occupancy and cognitive function: a monkey PET study with [(11)C] (+)3-MPB. Neuroimage 2011; 58: 1–9.

39. Skuskin D, Kay G, Tannenbaum C, et al. Trospium chloride has no effect on memory testing and is assay undetectable in the central nervous system of older patients with overactive bladder. Int J Clin Pract 2010; 64: 1294–1300.

40. Kay GG, Abou-Donia MB, Messer WS Jr, et al. Antimuscarinic drugs for overactive bladder and their potential effects on cognitive function in older patients. J Am Geriatr Soc 2005; 53: 2195–2201.

41. Wagg A, Dale M, Trettter R, et al. Randomised, multicentre, placebo-controlled, double-blind crossover study investigating the effect of solifenacin and oxybutynin in elderly people with mild cognitive impairment: the SENIOR study. Eur Urol 2013; 64: 74–81.

42. Kay GG, Maruff P, Scholfield D, et al. Evaluation of cognitive function in healthy older subjects treated with fesoterodine. Postgrad Med 2012; 124: 7–15.

43. Gibson W, Athanasopoulos A, Goldman H, et al. Are we shortchanging frail older people when it comes to the pharmacological treatment of urgency urinary incontinence? Int J Clin Pract 2014; 68: 1165–1173.

44. Herr M, Robine JM, Pinot J, et al. Polypharmacy and frailty: prevalence, relationship, and impact on mortality in a French sample of 2350 old people. Pharmacoepidemiol Drug Saf 2015; 24: 637–646.

45. Laroche ML, Charmes JP, Nouaille Y, et al. Is inappropriate medication use a major cause of adverse drug reactions in the elderly? Br J Clin Pharmacol 2007; 63: 177–186.

46. Richardson K, Fox C, Maidment I, et al. Anticholinergic drugs and risk of dementia: case–control study. BMJ 2018; 361: k1315.

47. Salahudeen MS, Chyou TY and Nishtala PS. Serum anticholinergic activity and cognitive and functional adverse outcomes in older people: a systematic review and meta-analysis of the literature. PLoS One 2016; 11: e0151084.

48. Wagg A, Gibson W, Ostaszkiewicz J, et al. Urinary incontinence in frail elderly persons: report from the 5th International Consultation on Incontinence. Neurourol Urodyn. Epub ahead of print 2 April 2014. DOI: 10.1002/nau.22602.

49. Arch JR, Ainsworth AT, Kawthorne MA, et al. Atypical beta-adrenoceptor on brown adipocytes as target for anti-obesity drugs. Nature 1984; 309: 163–165.

50. Yamaguchi O. Beta3-adrenoceptors in human detrusor muscle. Urology 2002; 59(S Suppl. 1): 25–29.

51. Sacco E, Bientinesi R, Tienforti D, et al. Discovery history and clinical development of mirabegron for the treatment of overactive bladder and urinary incontinence. Expert Opin Drug Discov 2014; 9: 433–448.

52. Takasu T, Ukai M, Sato S, et al. Effect of (R)-2-[(2-aminothiazol-4-yl)-4′-[(2-(hydroxy-2-phenylethyl)amino]ethyl) acetamidile (YM178), a novel selective beta3-adrenoceptor agonist, on bladder function. J Pharmacol Exp Ther 2007; 321: 642–647.

53. Yoshida M, Takeda M, Gotoh M, et al. Vibegron, a novel potent and selective beta3-adrenoceptor agonist, for the treatment of patients with overactive bladder: a randomized, double-blind, placebo-controlled phase 3 study. Eur Urol 2018; 73: 783–790.

54. Khullar V, Amarengo G, Angulo JC, et al. Efficacy and tolerability of mirabegron, a beta(3)-adrenoceptor agonist, in patients with overactive bladder: results from a randomised European–Australian phase 3 trial. Eur Urol 2013; 63: 283–295.

55. Nitti VW, Khullar V, van Kerrebroeck P, et al. Mirabegron for the treatment of overactive bladder: a prespecified pooled efficacy analysis and pooled safety analysis of three randomised, double-blind, placebo-controlled, phase III studies. Int J Clin Pract 2013; 67: 619–632.

56. Mangera A, Chapple CR, Kopp ZS, et al. The placebo effect in overactive bladder syndrome. Nat Rev Urol 2011; 8: 495–503.

57. Herschorn S, Barkin J, Castro-Diaz D, et al. A phase III, randomized, double-blind, parallel-group, placebo-controlled, multicentre study to assess the efficacy and safety of the beta(3) adrenoceptor agonist, mirabegron, in patients with symptoms of overactive bladder. Urology 2013; 82: 313–320.

58. Wagg AS, Newman DK, Leichsenring K, et al. Developing an internationally-applicable service specification for continence care: systematic review, evidence synthesis and expert consensus. PLoS One 2014; 9: e104129.

59. Chapple CR, Kaplan SA, Mitcheson D, et al. Randomized double-blind, active-controlled phase 3 study to assess 12-month safety and efficacy of mirabegron, a beta(3)-adrenoceptor agonist.
agonist, in overactive bladder. *Eur Urol* 2013; 63: 296–305.

60. Cui Y, Zong H, Yang C, et al. The efficacy and safety of mirabegron in treating OAB: a systematic review and meta-analysis of phase III trials. *Int Urol Nephrol* 2014; 46: 275–284.

61. Khullar V. Patient-reported outcomes and different approaches to urinary parameters in overactive bladder: what should we measure? *Int Urogynecol J* 2012; 23: 179–192.

62. Castro-Diaz D, Chapple CR, Hakimi Z, et al. The effect of mirabegron on patient-related outcomes in patients with overactive bladder: the results of post hoc correlation and responder analyses using pooled data from three randomized phase III trials. *Qual Life Res* 2015; 24: 1719–1727.

63. Wagg AS, Foley S, Peters J, et al. Persistence and adherence with mirabegron vs antimuscarinics in overactive bladder: retrospective analysis of a UK General Practice prescription database. *Int J Clin Pract*. Epub ahead of print 14 September 2017. DOI: 10.1111/ijcp.12996.

64. Freemantle N, Ginsberg DA, McCool R, et al. Comparative assessment of onabotulinumtoxinA and mirabegron for overactive bladder: an indirect treatment comparison. *BMJ Open* 2016; 6: e009122.

65. Abrams P, Kelleher C, Staskin D, et al. Combination treatment with mirabegron and solifenacin in patients with overactive bladder: efficacy and safety results from a randomised, double-blind, dose-ranging, phase 2 study (Symphony). *Eur Urol* 2015; 67: 577–588.

66. Herschorn S, Chapple CR, Abrams P, et al. Efficacy and safety of combinations of mirabegron and solifenacin compared with monotherapy and placebo in patients with overactive bladder (SYNERGY study). *BJU Int* 2017; 120: 562–575.

67. Drake MJ, Chapple C, Esen AA, et al. Efficacy and safety of mirabegron add-on therapy to solifenacin in incontinent overactive bladder patients with an inadequate response to initial 4-week solifenacin monotherapy: a randomised double-blind multicentre phase 3b study (BESIDE). *Eur Urol* 2016; 70: 136–145.

68. Gibson W, MacDiarmid S, Huang M, et al. Treating overactive bladder in older patients with a combination of mirabegron and solifenacin: a prespecified analysis from the BESIDE study. *Eur Urol Focus* 2017; 3: 629–638.

69. MacDiarmid S, Al-Shukri S, Barkin J, et al. Mirabegron as add-on treatment to solifenacin in patients with incontinent overactive bladder and an inadequate response to solifenacin monotherapy. *J Urol* 2016; 196: 809–818.

70. Coyne K, Revicki D, Hunt T, et al. Psychometric validation of an overactive bladder symptom and health-related quality of life questionnaire: the OAB-q. *Qual Life Res* 2002; 11: 563–574.

71. Coyne KS, Matza LS, Kopp Z, et al. The validation of the patient perception of bladder condition (PPBC): a single-item global measure for patients with overactive bladder. *Eur Urol* 2006; 49: 1079–1086.